Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc., trading under the ticker DECA, is the combined company formed through the business combination of Decathlon Acquisition Corp. and clinical-stage pharmaceutical company Semnur Pharmaceuticals. Decathlon Acquisition Corp. completed its IPO in 2021 as a healthcare-focused blank-check company. Semnur, which is developing treatments in the pain-management space, filed an 8-K with the SEC on September 26, 2025, under accession number 0001193125-25-220455, reflecting ongoing public-company reporting obligations following the de-SPAC transaction. The combined entity operates in the biopharmaceutical sector. Visit SpacDesk and sign up for full data, filings history, and deal analytics on DECA and hundreds of other SPAC transactions.